US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.89
▼-1.02%
TSLA
$378.69
▲+2.18%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.89
▼-1.02%
TSLA
$378.69
▲+2.18%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Annexon, Inc. - common stock
(NQ:
ANNX
)
4.200
+0.010 (+0.24%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Annexon, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
September 24, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Participate in Upcoming September Investor Conferences
September 02, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon (ANNX) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
GBS and geographic atrophy programs advance toward 2026-2027 regulatory submissions.
Via
The Motley Fool
Topics
Earnings
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Q2 Earnings Call Highlights
↗
August 12, 2026
Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month...
Via
MarketBeat
Topics
Earnings
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
August 12, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
August 06, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
July 30, 2026
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
July 14, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
↗
June 09, 2026
Annexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the...
Via
MarketBeat
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
↗
June 04, 2026
Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference,...
Via
MarketBeat
Annexon to Participate in Upcoming June Investor Conferences
May 27, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
↗
May 14, 2026
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting...
Via
MarketBeat
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 07, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present at the Bank of America Securities Health Care Conference 2026
May 06, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
April 01, 2026
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive...
Via
MarketMinute
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 30, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
February 17, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday?
↗
January 12, 2026
Via
Chartmill
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
January 12, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
January 08, 2026
From
Annexon Biosciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
